SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Collaboration › Details

Merck (DE)–Ablynx: Nanobodies, 201111– collab co-discovery + co-developm Nanobodies against two targets in osteoarthritis Merck Serono


Period Period 2011-11-01
  Predecessor Merck (DE)–Ablynx: Nanobodies, 201010– collab co-discovery + co-developm Nanobodies against one target in inflammation Merck Serono
  Successor Merck (DE)–Ablynx: Nanobodies, 201309– collab co-discovery + co-developm Nanobodies extension Merck Serono
Organisations Partner, 1st Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
  Partner, 2nd Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
  Group Ablynx (Group)
Products Product Nanobodies®
  Product 2 drug discovery

Ablynx N.V.. (6/21/13). "Press Release: Ablynx’s Partner Initiates a Phase I Study and Doses First Healthy Volunteer with ALX-0761". Ghent.

Ablynx [Euronext Brussels: ABLX] today announced that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of the Nanobody®, ALX-0761, for the treatment of inflammatory diseases.

ALX-0761 is the first clinical Nanobody candidate to emerge from the collaboration which the companies entered into in 2008.

The collaboration agreement allows Ablynx to convert, at certain time-points in the development, the 50-50 co-discovery and co-development collaboration into a license agreement. At this point, Ablynx has decided to convert this collaboration into a license agreement, and as a result, Merck Serono now has an exclusive worldwide license agreement for ALX-0761. Ablynx is eligible to receive additional development milestone payments associated with the progress of the product in multiple indications as well as regulatory and commercial milestones plus tiered royalties upon approval of the product. The start of the Phase I study triggers a €2.5 million milestone payment to Ablynx.

The Phase I study involves a single-centre, randomised, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics and pharmacodynamics of single ascending doses of subcutaneous injections with ALX-0761 in healthy subjects.

"We are very pleased to see our first programme with Merck Serono advancing into clinical development, less than five years since the start of our collaboration," said Dr Edwin Moses, Chairman and CEO of Ablynx. "We have now reached the point at which we will rely on Merck Serono's considerable resources and expertise to take this programme forward. We remain committed to continue to work closely with our partner not only on ALX-0761 but on the other four co-discovery and co-development programmes where we are currently collaborating."

About the Merck Serono partnerships

In September 2008, Ablynx entered into an agreement with Merck Serono under which Merck Serono and Ablynx co-discover and co-develop Nanobodies against two targets in immunology and oncology. Both companies agreed to share equally all research and development costs and the resulting profits. Ablynx has options to opt-out during the research and development programmes.

In October 2010, Ablynx and Merck Serono entered into a second co-discovery and co-development agreement to develop Nanobodies against one single target in inflammation. Ablynx received an upfront fee and retained full control to drive the process up to the investigational new drug (IND) application.

In November 2011, Ablynx and Merck announced that they have further expanded their relationship and entered into a third agreement to co-discover and co-develop Nanobodies against two targets in osteoarthritis. Ablynx received an upfront fee and will be fully responsible for all activities and costs for each programme, excluding manufacturing costs and costs relating to certain in vivo models, up to the delivery of the pre-clinical package that will form the basis of an IND filing or IND equivalent filing.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies are at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on

For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Record changed: 2017-05-22


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Merck (DE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top